NCT00422604View on ClinicalTrials.gov

Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

salmeterol

DRUG

tiotropium

DRUG

GSK233705

Trial Locations (11)

22927

GSK Investigational Site, Großhansdorf

65187

GSK Investigational Site, Wiesbaden

00029

GSK Investigational Site, Helsinki

7609 PP

GSK Investigational Site, Almelo

5623 EJ

GSK Investigational Site, Eindhoven

6419 PC

GSK Investigational Site, Heerlen

5504 DB

GSK Investigational Site, Veldhoven

105 229

GSK Investigational Site, Moscow

197 089

GSK Investigational Site, Saint Petersburg

SL1 2AD

GSK Investigational Site, Upton Road, Slough

M23 9QZ

GSK Investigational Site, Manchester

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00422604 - Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter